Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis


Bristol Myers Squibb & Co BMY has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety of Zeposia (ozanimod) in active ulcerative colitis (UC). 

  • Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement, and corticosteroid-free remission was maintained through Week 142. 
  • No new safety signals emerged in the study. 
  • Related: Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis.
  • Interim analysis of patients (n=823) showed that at Weeks 46, 94, and 142, 45%, 51%, and 45% of participants were in clinical remission, respectively, and 80%, 84%, and 86% achieved clinical response, respectively. 
  • The efficacy of Zeposia in those who entered the long-term study as responders on Day 1 was higher compared to the total population, with 70% and 69% achieving clinical remission at Weeks 46 and 94, respectively, and 95% and 98% achieving clinical response at Weeks 46 and 94, respectively. 
  • Price Action: BMY shares are down 0.30% at $67.40 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!